Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Umbilical Cord Blood Transplant Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have one of the following disease types with disease-specific features as outlined in the protocol:~  * Acute myeloid leukemia (AML)~ * Acute lymphoblastic leukemia (ALL)~ * Myelodysplasia~ * Chronic myelogenous leukemia~ * Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma~ * Hodgkin's lymphoma~ * Relapsed Multiple Myeloma~* At least 35 days following start of preceding leukemia induction cytotoxic chemotherapy~* Patient age 18-55 years~* Karnofsky Performance status ≥ 70%~* No availability of a consenting HLA-matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB1.~* No availability of a readily available HLA-matched volunteer unrelated donor (8 of 8 allele match at HLA-A, -B, -C and -DRB1). Patients with unstable disease who are in danger of significant disease progression while waiting to procure volunteer donor cells will be eligible to be treated on this protocol, even if a matched donor is available.~* Patients must have a matched or partially matched UCB unit with greater than 1.8 x10-7 nucleated cells/kg of recipient weight at the time of cryopreservation.~* No current uncontrolled bacterial, viral or fungal infection (defined as currently taking medication and progression of clinical symptoms).~* No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.~* Non pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks.~* Required baseline laboratory values as defined in the protocol~Exclusion Criteria:~* Symptomatic uncontrolled coronary artery disease or congestive heart failure.~* Severe hypoxemia with room air PaO2 less than 70, supplemental oxygen dependence, or DLCO less than 50 percent predicted~* Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy~* Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin once per day (Type: EXPERIMENTAL): 600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
- Sitagliptin twice per day (Type: EXPERIMENTAL): 600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
- Sitagliptin three times per day (Type: EXPERIMENTAL): 600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).